Prospects for anti-ras drugs

British Journal of Haematology

Volumn 116, Issue 3, 2002, Pages 511-518

  Ahmadian, Mohammad Reza ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

Anticancer drug; GTPase; Oncogene; Ras; Signal transduction

Indexed keywords

GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; RNA; SULINDAC SULFIDE;

CANCER; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; GENES, RAS; GTP PHOSPHOHYDROLASES; HUMANS; NEOPLASMS; RAS PROTEINS;

EID: 0036178826     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2001.03314.x     Document Type: Review

References (99)

1. Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy
2. Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras
3. Guanosine triphosphatase stimulation of oncogenic Ras mutants
4. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing
5. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
6. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
7. Ras oncogenes: Their role in neoplasia
8. In vitro inhibition of Ras-Raf association by short peptides
9. RAS and leukemia: From basic mechanisms to gene-directed therapy
10. Quantitative structure-activity analysis correlating Ras-Raf interaction in vitro to Raf activation in vivo
11. Proteins regulating Ras and its relatives
12. Ras oncogenes in human cancer: A review
13. The GTPase superfamily: A conserved switch for diverse cell functions
14. The GTPase superfamily: Conserved structure and molecular mechanism
15. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma
16. Increasing complexity of Ras signaling
17. Protein prenyltransferases
18. GEFs: Structural basis for their activation of small GTP-binding proteins
19. Endomembrane trafficking of ras: The CAAX motif targets proteins to the ER and Golgi
20. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function
21. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
22. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity
23. Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus
24. Control of ras activation
25. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
26. Kinetics of interaction between normal and proline 12 Ras and the GTPase-activating proteins, p120-GAP and neurofibromin. The significance of the intrinsic GTPase rate in determining the transforming ability of ras
27. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
28. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway
29. Farnesyl transferase inhibitors: Current developments and future perspectives
30. RNA-triggered gene silencing
31. COX-2 and colon cancer: Potential targets for chemoprevention
32. A novel mechanism for guanosine triphosphate binding protein inactivation - Mechanism of DABP-GTP cleavage
33. Selective GRB2 SH2 inhibitors as anti-Ras therapy
34. Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: The C-terminal domain of GAP is not sufficient for full activity
35. RNA aptamers that specifically bind to a K Ras-derived farnesylated peptide
36. The prevention of colorectal cancer by aspirin use
37. Aptamers as reagents for high-throughput screening
38. Dislodgment and accelerated degradation of Ras
39. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells
40. All ras proteins are polyisoprenylated but only some are palmitoylated
41. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane
42. Ras and its effectors
43. Sulindac sulfide inhibits Ras signaling
44. Inhibition of RAS-targeted prenylation: Protein farnesyl transferase inhibitors revisited
45. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia
46. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
47. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes
48. Ras effectors and their role in mitogenesis and oncogenesis
49. The new Sulindac derivative IND 12 reverses Ras induced cell transformation
50. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
51. RNA aptamers that specifically bind to the Ras-binding domain of Raf-1
52. RAS inhibitors: Potential for cancer therapeutics
53. Concepts in Ras-directed therapy
54. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
55. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
56. Substrate assisted catalysis - Application to G proteins
57. Nanoparticulate systems for the delivery of antisense oligonucleotides
58. Antisense oligonucleotides: Promise and reality
59. Ras farnesyltransferase: A new therapeutic target
60. Function and regulation of ras
61. Interactions between Ras proteins and their effectors
62. New insights into the interaction of Ras with the plasma membrane
63. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid
64. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
65. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using Light Cycler technology
66. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
67. Farnesyltransferase inhibitors: Antineoplastic properties, mechanisms of action, and clinical prospects
68. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228
69. Inhibition of purified p21ras farnesyl: Protein transferase by Cys-AAX tetrapeptides
70. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
71. The Ras branch of small GTPases: Ras family members don't fall far from the tree
72. Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent
73. The role of ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation
74. The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants
75. GTPase-activating proteins: Helping hands to complement an active site
76. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice
77. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
78. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
79. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
80. Understanding Ras: It ain't over "til it's over"
81. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
82. Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex
83. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
84. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants
85. The role of oncogenic kinases in human cancer
86. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors
87. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1
88. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice
89. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
90. Signal transduction via Ras
91. How Ras-related proteins talk to their effectors
92. Ras, a molecular switch involved in tumor formation
93. Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1
94. Protein prenylation: Molecular mechanisms and functional consequences
95. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype
96. Rescue of a mutant G-protein by substrate-assisted catalysis
97. GTP analogue hydrolysis by the Gs protein: Implication for the role of catalytic glutamine in the GTPase reaction
98. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
99. Ras and Rap1: Two highly related small GTPases with distinct function